CSIMarket Company Name, Ticker, Competitors, else..
 
Longeveron Inc   (NASDAQ: LGVN)
 
Price: $6.6400 $0.06 0.912%
Day's High: $6.799900054931641 Week Perf: 0.91 %
Day's Low: $ 6.50 30 Day Perf: 859.54 %
Volume (M): 58,892 52 Wk High: $ 7.40
Volume (M$): $ 0 52 Wk Avg: $0.98
Open: $6.52 52 Wk Low: $0.47



 Market Capitalization (Millions $) 208
 Shares Outstanding (Millions) 31
 Employees 38
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Longeveron Inc is a biotechnology company that specializes in the development of innovative cellular therapies aimed at improving the health and longevity of individuals. The company focuses on researching and developing regenerative medicine products derived from adult stem cells. Their therapies target various medical conditions such as Alzheimer's disease, aging frailty, metabolic syndrome, and other age-related diseases. Longeveron Inc aims to harness the regenerative potential of stem cells to provide new treatment options that enhance overall health and extend human lifespan.


   Company Address: 1951 NW 7th Avenue Miami 33136 FL
   Company Phone Number: 909-0840   Stock Exchange / Ticker: NASDAQ LGVN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX   -2.56%    
ISCO        15.38% 
ORGO   -9.45%    
OVID   -4.86%    
RGBP      0% 
SBFM   -7.69%    
• View Complete Report
   



Management Announcement

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

Published Tue, Apr 22 2025 8:05 PM UTC

Longeveron Inc.: Strategic Movements and Financial Insights Amidst ChallengesLongeveron Inc. a groundbreaking company in the field of cellular therapies, recently released a letter to its shareholders detailing its corporate strategy, significant advancements, and primary objectives for 2025. This communication comes at a crucial time for the organization, which is navigati...
Management Changes

Longeveron Appoints Devin Blass as CTO, Prepares for BLA Filing Amid Financial Challenges and Focus on Alzheimer’s Therapy,

Published Mon, Nov 11 2024 2:05 PM UTC

In a significant move aimed at bolstering its strategic framework and advancing its scientific endeavors, Longeveron Inc. a pioneering entity in cellular therapies, has announced the appointment of Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing and Controls (CMC), effective December 2, 2024. This transition comes at a pivo...
Clinical Study

A Convergence of Scientific Ingenuity Longeveron’s Participation in the Esteemed Alliance for Regenerative Medicine...

Published Thu, Sep 26 2024 1:05 PM UTC

In the year of our Lord two thousand and twenty-three, within the hallowed halls of scientific discourse, the venerable firm, Longeveron, prepares to grace the illustrious Alliance for Regenerative Medicine’s distinguished convening, known as the Cell & Gene Meeting on the Mesa. This momentous event, a veritable symposium of the foremost minds in the realm of regenerative ...
Clinical Study

Navigating the Regulatory Landscape Longeverons Lomecel-B and the Future of Rare Pediatric Cardiac Disease Treatment

Published Tue, Sep 3 2024 1:01 PM UTC

The intersection of healthcare innovation and regulatory frameworks is a pivotal area in the pharmaceutical sciences, especially for diseases that are rare and challenging to treat, such as Hyoplastic Left Heart Syndrome (HLHS). Longeveron, a clinical-stage biotechnology company, stands at the forefront of this narrative with its investigational product, Lomecel-B. Recent a...
Stocks on the Move

Navigating the Emotional Landscape Longeveron Inc.s Rollercoaster Journey Through FDA Endorsements and Market Realities,

Published Thu, Aug 15 2024 8:48 AM UTC

Longeveron Inc. (NASDAQ: LGVN), a Miami-based clinical-stage biotechnology firm, has experienced significant fluctuations in its stock price over the past several weeks. Following the recent announcement of a $9 million registered direct offering and subsequent FDA Fast Track designation for its lead product Lomecel-B in the treatment of mild Alzheimer’s disease, investor...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 175.52
Price to Sales (Expected) -
Price to Book 20.03
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.2
Working Capital Ratio 4.5
Leverage Ratio (MRQ) 0.49
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.99 $
Revenues (TTM) 0.04 $
Cash Flow (TTM) 0.17 $
Cash 0.58 $
Book Value 0.33 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 31,237
Net Income per Employee (TTM) -617,737
Receivable Turnover Ratio (TTM) 16.43
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.06

Profitability Ratios Current
Gross Margin (MRQ) 63.41 %
Operating Margin (MRQ) -2150.17 %
Net Margin (MRQ) -2116.03 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Longeveron Inc's Segments
Clinical trial revenue    231.71 % of total Revenue
Reportable Segment    6.97 % of total Revenue
Reportable Segment Aggregation Before Other Operating Segment    238.68 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.